Results 71 to 80 of about 46,431 (310)
The Addie E. Davis collection contains papers from her years at Southeastern Baptist Theological Seminary, sermons and bulletins from church services, audio tapes of sermons, and miscellaneous personal papers and publications.The Addie E.
core
Pathogenic PF4/Polyanion ELISA‐Negative Antibodies in HIT
ABSTRACT Background Platelet factor 4‐polyanion enzyme‐linked immunosorbent assays (ELISAs) are considered highly sensitive for diagnosing heparin‐induced thrombocytopenia (HIT), such that current practice guidelines recommend use of ELISA‐negative results to exclude HIT.
Adam J. Kanack +25 more
wiley +1 more source
This study aims to determine the feasibility of interactive flipbook media as learning media, determine student responses to interactive flipbook media with the STM (Science Technology Society) approach and improve student learning outcomes in learning ...
Yofi Parmita +2 more
doaj +1 more source
ABSTRACT Talquetamab is a GPRC5D × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). This is the first real‐world study to comprehensively report muco‐cutaneous toxicities, infections, and efficacy of talquetamab in 151 patients across five countries with the longest follow‐up reported enabling better efficacy and ...
Murali Janakiram +94 more
wiley +1 more source
This study aims to develop an E-Booklet utilizing endophytic fungi isolated from the roots of Phalaenopsis amabilis to improve learning outcomes of Kingdom Fungi material for class X MA Zainul Bahar students, Bondowoso.
Sri Wulandari +2 more
doaj +1 more source
Addie M. Weed, interviewed by Edward D. “Sandy” Ives, Part 1
Addie M. Weed, interviewed by Edward D. Sandy Ives in her Veazie, Maine home, October 7, 1975. Weed, age 92, speaks about her life and the history of her State Street home and property in Veazie, Maine. Listen Part 1.
Weed, Addie Matilda
core
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez +17 more
wiley +1 more source
Addie M. Weed, interviewed by Edward D. “Sandy” Ives, Part 6
Addie M. Weed, interviewed by Edward D. Sandy Ives in her Veazie, Maine home, October 7, 1975. Weed, age 92, speaks about her life and the history of her State Street home and property in Veazie, Maine. ListenPart 1.
Weed, Addie Matilda
core
ABSTRACT Autosomal recessive loss‐of‐function variants in PPP1R13L cause an ultra‐rare cardiocutaneous syndrome characterized by rapidly progressive arrhythmogenic cardiomyopathy (ACM). PPP1R13L encodes iASPP, which has two potentially overlapping mechanisms driving ACM as both a regulator of NFκB‐mediated inflammation and a binding partner within the ...
Aaron Renberg +9 more
wiley +1 more source

